StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) company profile

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

About Xeris Biopharma

Pharmaceutical Preparations, SIC 2834

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with chronic endocrine and neurological conditions. Its commercial portfolio includes Recorlev, a cortisol synthesis inhibitor prescribed for adults with endogenous Cushing’s syndrome who cannot undergo or have not been cured by surgery; Gvoke, a ready-to-use liquid glucagon administered for severe hypoglycemia in pediatric and adult diabetes patients; and Keveyis, a treatment for primary periodic paralysis. The company also advances development pipeline candidates such as XP-8121 for hypothyroidism and collaborates with external pharmaceutical partners using its proprietary formulation platforms.

The company focuses its commercial operations within the United States. Xeris relies on third-party contract manufacturing organizations and logistics providers across several domestic and international locations—including Illinois, Florida, California, Switzerland, and Taiwan—for product formulation, device sub-assembly, packaging, and distribution to wholesale customers and specialty pharmacies. The provided text does not state the location of the company's headquarters.

Summary of the business section of Xeris Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Xeris Biopharma Holdings, Inc.
Headquarters
Chicago, IL
Address
1375 West Fulton Street, Suite 1300 60607
Phone
(844) 445-5704
Employees
435, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Grand Rapids, Michigan

Stock & identifiers

Ticker
XERS
Exchange
Nasdaq
IPO date
Jun 21, 2018
Shares outstanding
182M, Jul 31, 2026
Public float
$731.10M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1867096
CUSIP
98422E103
ISIN
US98422E1038
FIGI
BBG012V1MG52
Share class FIGI
BBG012V1MG61
EIN
87-1082097

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John Patrick Shannon JrSee Remarks, Director2,898,933
Kevin McCullochSee Remarks1,584,208
Steven PieperSee Remarks1,346,053
Beth HechtSee Remarks1,086,130
Anh Tu NguyenSee Remarks402,234
Kenneth Erland JohnsonSee Remarks346,288
Menassie TaddeseDirector22,365
Nerissa KreherDirector33,582
John JohnsonDirector683,083
Dawn HalkuffDirector124,603
James Aloysius BradyDirector113,359
Marla PerskyDirector157,063
Garheng KongDirector238,337
Barbara-Jean Anne Bormann-KennedyDirector150,693
Jeffrey W. ShermanDirector224,588

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.04M$11.99M$2.01M$160$125
FY2024
John P.Shannon
$3.83M$5.58M$2.03M$69$93
FY2024
Paul R.Edick
$6.83M$8.46M$2.03M$69$93
FY2023$2.14M$3.46M$1.33M$48$94
FY2022$2.81M$1.02M$1.40M$27$90
FY2021$3.76M$2.29M$1.65M$60$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
John Shannon
Chief Executive Officer
$742.33K$2.85M$838.62K$607.97K$5.66K$5.04M+32%
Steven M. Pieper
Chief Financial Officer
$505.39K$658.60K$419.31K$286.56K$4.23K$1.87M+1%
Kevin McCulloch
President and Chief Operating Officer
$543.83K$658.60K$698.85K$342.62K$27.08K$2.27M-12%
Beth P. Hecht
Chief Legal Officer and Corporate Secretary
$517.09K$658.60K$419.31K$293.19K$7.09K$1.90M-27%
Anh Nguyen
Chief Medical Officer
$409.23K$1.13M$218.95K$232.03K$12.44K$2.00M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 435 full-time employees in the United States, 216 of whom were primarily engaged in sales and marketing, 169 of whom were primarily engaged in general administration, and 50 of whom were primarily engaged in product development and research.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?